{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:22:14Z","timestamp":1791580934605,"version":"4.3.4"},"reference-count":46,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>High-grade B-cell lymphoma with \"double-hit\" MYC and BCL2 rearrangements (HGBCL-DH-BCL2) is associated with poor outcomes following standard chemoimmunotherapy, prompting dose-intensive regimen use. However, the benefit of intensification is unclear due to rarity precluding randomized trials, and selection bias in retrospective comparisons. In 2015, BC Cancer introduced a provincial guideline recommending dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) for fit patients aged \u226475 years with HGBCL-DH-BCL2 identified by routine cytogenetic testing. To assess this guideline\u2019s impact, we compared the outcomes of patients with de novo HGBCL-DH-BCL2 tumors of diffuse large B-cell lymphoma (DLBCL) morphology across 2 eras. The DA-EPOCH-R era (2015-2020) included patients diagnosed after guideline implementation. The historic era (2005-2010) included patients identified from a historic province-wide cohort of patients with DLBCL morphology tumors that underwent universal cytogenetic testing in a research setting, predominantly treated with standard chemoimmunotherapy. Two-year overall survival (OS) was significantly improved in the DA-EPOCH-R vs historic era (75% vs 47%, P = .008) in HGBCL-DH-BCL2, whereas OS remained unchanged in DLBCL, not otherwise specified (78% vs 76%, P = .17). Within HGBCL-DH-BCL2, tumors harboring immunoglobulin MYC partner loci (43%) and those expressing the dark-zone signature (77%) were associated with the most substantial survival improvements. In a contemporary cohort of HGBCL-DH-BCL2 histologically transformed from follicular lymphoma (FL) in the DA-EPOCH-R era, outcomes of patients who were chemoimmunotherapy-na\u00efve were comparable to those with de novo disease, whereas patients treated with chemoimmunotherapy for FL prior to transformation had poor outcomes. These data support using DA-EPOCH-R in select patients with HGBCL-DH-BCL2 of DLBCL morphology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017282","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:09:56Z","timestamp":1760123396000},"page":"320-333","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with\n                    <i>MYC<\/i>\n                    \/\n                    <i>BCL2<\/i>\n                    rearrangements, DLBCL morphology"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-5371","authenticated-orcid":false,"given":"Waleed","family":"Alduaij","sequence":"first","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6921-2018","authenticated-orcid":false,"given":"Jean-Nicolas","family":"Champagne","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"3Hematology and Medical Oncology, H\u00f4pital du Sacre-Coeur de Montr\u00e9al, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-2798","authenticated-orcid":false,"given":"Brett","family":"Collinge","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2867-4037","authenticated-orcid":false,"given":"Susana","family":"Ben-Neriah","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-7595","authenticated-orcid":false,"given":"Aixiang","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-0103","authenticated-orcid":false,"given":"Merrill","family":"Boyle","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Meissner","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-9391","authenticated-orcid":false,"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-3258","authenticated-orcid":false,"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"5Department of Pathology, University of Virginia Health System, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"6Department of Blood and Marrow Transplant and Cellular Therapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-2742","authenticated-orcid":false,"given":"Andrew J.","family":"Mungall","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"7Canada\u2019s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-9750","authenticated-orcid":false,"given":"Christian","family":"Steidl","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"4Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada"},{"name":"2Division of Medical Oncology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"21","key":"2026012709470771700_bib1","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198805263182106","article-title":"Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma","volume":"318","author":"De Jong","year":"1988","journal-title":"N Engl J Med"},{"issue":"7","key":"2026012709470771700_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026012709470771700_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026012709470771700_bib4","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"issue":"S2","key":"2026012709470771700_bib5","first-page":"111","article-title":"The mutational landscape of double\/triple-hit high-grade B-cell lymphoma with BCL2 rearrangement- (DH\/TH-BCL2) \u2013 an LLMPP project","volume":"39","author":"Collinge","year":"2021","journal-title":"Hematological Oncol"},{"issue":"4","key":"2026012709470771700_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"2026012709470771700_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026012709470771700_bib8","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026012709470771700_bib9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026012709470771700_bib10","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood-2015-06-649905","article-title":"Cell of origin of transformed follicular lymphoma","volume":"126","author":"Kridel","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2026012709470771700_bib11","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood.2019002600","article-title":"The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH","volume":"134","author":"Hilton","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026012709470771700_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2024024251","article-title":"Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)","volume":"144","author":"Hilton","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026012709470771700_bib13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2026012709470771700_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3324\/haematol.2018.190157","article-title":"Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements is not associated with MYC\/IG gene rearrangements","volume":"103","author":"McPhail","year":"2018","journal-title":"Haematologica"},{"issue":"35","key":"2026012709470771700_bib15","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026012709470771700_bib16","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026012709470771700_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ejh.12212","article-title":"MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC\/BCL2 translocations","volume":"92","author":"Pedersen","year":"2014","journal-title":"Eur J Haematol"},{"issue":"15","key":"2026012709470771700_bib18","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2026012709470771700_bib19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026012709470771700_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2026012709470771700_bib21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"2026012709470771700_bib22","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"21","key":"2026012709470771700_bib23","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026012709470771700_bib24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.26068","article-title":"First-line treatment of double-hit and triple-hit lymphomas: survival and tolerance data from a retrospective multicenter French study","volume":"96","author":"Laude","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2026012709470771700_bib25","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2022.281461","article-title":"Modern, real-world patterns of care and clinical outcomes among patients with newly diagnosed diffuse large B-cell lymphoma with or without double\/triple-hit status in the United States","volume":"108","author":"Goyal","year":"2023","journal-title":"Haematologica"},{"issue":"15","key":"2026012709470771700_bib26","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1182\/blood.2024025603","article-title":"Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2","volume":"144","author":"Collinge","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026012709470771700_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"28","key":"2026012709470771700_bib28","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026012709470771700_bib29","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026012709470771700_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1182\/blood.2020005846","article-title":"Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP","volume":"137","author":"Freeman","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2026012709470771700_bib31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clml.2014.12.015","article-title":"Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M\/IVAC with Rituximab followed by hematopoietic stem cell transplantation","volume":"15","author":"Sun","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2026012709470771700_bib32","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1182\/bloodadvances.2023010402","article-title":"Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study","volume":"7","author":"Urata","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2026012709470771700_bib33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"8","key":"2026012709470771700_bib34","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2026012709470771700_bib35","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/bloodadvances.2019000875","article-title":"Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics","volume":"4","author":"Torka","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2026012709470771700_bib36","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/bloodadvances.2019000251","article-title":"COO and MYC\/BCL2 status do not predict outcome among patients with stage I\/II DLBCL: a retrospective multicenter study","volume":"3","author":"Barraclough","year":"2019","journal-title":"Blood Adv"},{"issue":"25","key":"2026012709470771700_bib37","doi-asserted-by":"crossref","first-page":"38122","DOI":"10.18632\/oncotarget.9473","article-title":"Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC\/BCL2 double hit lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"26","key":"2026012709470771700_bib38","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic specialized program of research excellence molecular epidemiology resource","volume":"31","author":"Link","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012709470771700_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12570","article-title":"Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database","volume":"163","author":"Ban-Hoefen","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2026012709470771700_bib40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.2019000258","article-title":"Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma","volume":"134","author":"Freeman","year":"2019","journal-title":"Blood"},{"issue":"25","key":"2026012709470771700_bib41","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.2023020780","article-title":"The high-grade B-cell lymphomas: double hit and more","volume":"144","author":"Davies","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026012709470771700_bib42","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"issue":"15","key":"2026012709470771700_bib43","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026012709470771700_bib44","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1182\/blood-2023-178623","article-title":"Deciphering the clinical benefit of pola-R-CHP versus R-CHOP in different genetic subtypes beyond cell of origin in the POLARIX study","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2026012709470771700_bib45","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood.2024025355","article-title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","volume":"145","author":"Tumuluru","year":"2025","journal-title":"Blood"},{"issue":"23","key":"2026012709470771700_bib46","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood.2024026831","article-title":"Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma","volume":"145","author":"Samples","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/320\/2497910\/blooda_adv-2025-017282-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/320\/2497910\/blooda_adv-2025-017282-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:47:18Z","timestamp":1769525238000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/320\/547660\/Population-wide-introduction-of-dose-adjusted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017282","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,14]]}}}